Genetics, diagnosis and future treatment strategies for primary ciliary dyskinesia

Bibliography

• Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009;34(6):1264-76
   PubMed Web of Science ®Google Scholar
• Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007;92(12):1136-40
   PubMed Web of Science ®Google Scholar
• Leigh MW, Pittman JE, Carson JL, et al. Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. Genet Med 2009;11(7):473-87
   PubMed Web of Science ®Google Scholar
• Zariwala MA, Knowles MR, Omran H. Genetic defects in ciliary structure and function. Annu Rev Physiol 2007;69:423-50
   PubMed Web of Science ®Google Scholar
• Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013;188(8):913-22
   PubMed Web of Science ®Google Scholar
• Kartagener M. Zur pathogenese der bronkiectasien. Bronkiectasien bei situs viscerum inversus. Beitr Klin Tuberk Spezif Tuberkuloseforsch 1933;83:489-501
   Google Scholar
• Afzelius BA. A human syndrome caused by immotile cilia. Science 1976;193(4250):317-19
   PubMed Web of Science ®Google Scholar
• Torgersen J. Transposition of viscera, bronchiectasis and nasal polyps; a genetical analysis and a contribution to the problem of constitution. Acta radiol 1947;28(1):17-24
   Web of Science ®Google Scholar
• Katsuhara K, Kawamoto S, Wakabayashi T, Belsky JL. Situs inversus totalis and Kartagener’s syndrome in a Japanese population. Chest 1972;61(1):56-61
   Google Scholar
• Leigh MW, Hazucha MJ, Chawla KK, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc 2013;10(6):574-81
   PubMedGoogle Scholar
• Sagel SD, Davis SD, Campisi P, Dell SD. Update of respiratory tract disease in children with primary ciliary dyskinesia. Proc Am Thorac Soc 2011;8(5):438-43
   Google Scholar
• Ferkol T, Leigh M. Primary ciliary dyskinesia and newborn respiratory distress. Semin Perinatol 2006;30(6):335-40
   Google Scholar
• Leigh MW, Shapiro AJ, Pittman JE, et al. Definition Of Clinical Criteria For Diagnosis Of Primary Ciliary Dyskinesia American Thoracic Society International Conference. Philadelphia, PA: Am Thorac Soc A2483-A83
   Google Scholar
• Pittman JE, Rosenfeld M, LaFave C, et al. Characteristics Of Primary Ciliary Dyskinesia In Children Under 5 Years Of Age. American Thoracic Society International Conference. Denver, CO. Am Thorac Soc 2011;A1213-A13
   Google Scholar
• Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007;188(5):1232-8
   PubMed Web of Science ®Google Scholar
• Jain K, Padley SP, Goldstraw EJ, et al. Primary ciliary dyskinesia in the paediatric population: range and severity of radiological findings in a cohort of patients receiving tertiary care. Clin Radiol 2007;62(10):986-93
   PubMed Web of Science ®Google Scholar
• Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008;134(2):351-7
   PubMed Web of Science ®Google Scholar
• Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010;181(11):1262-8
   PubMed Web of Science ®Google Scholar
• Brown DE, Pittman JE, Leigh MW, et al. Early lung disease in young children with primary ciliary dyskinesia. Pediatr Pulmonol 2008;43(5):514-16
   Google Scholar
• Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169(4):459-67
   PubMed Web of Science ®Google Scholar
• Francis RJ, Christopher A, Devine WA, et al. Congenital heart disease and the specification of left-right asymmetry. Am J Physiol Heart Circ Physiol 2012;302(10):H2102-11
   Google Scholar
• Nakhleh N, Francis R, Giese RA, et al. High prevalence of respiratory ciliary dysfunction in congenital heart disease patients with heterotaxy. Circulation 2012;125(18):2232-42
   PubMed Web of Science ®Google Scholar
• Brueckner M. Impact of genetic diagnosis on clinical management of patients with congenital heart disease: cilia point the way. Circulation 2012;125(18):2178-80
   Google Scholar
• Shapiro AJ, Davis SD, Ferkol T, et al. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest 2014;146(5):1176-86
   PubMed Web of Science ®Google Scholar
• Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation 2007;115(22):2814-21
   PubMed Web of Science ®Google Scholar
• Brueckner M. Heterotaxia, congenital heart disease, and primary ciliary dyskinesia. Circulation 2007;115(22):2793-5
   Google Scholar
• Sha YW, Ding L, Li P. Management of primary ciliary dyskinesia/Kartagener’s syndrome in infertile male patients and current progress in defining the underlying genetic mechanism. Asian J Androl 2014;16(1):101-6
   PubMed Web of Science ®Google Scholar
• Munro NC, Currie DC, Lindsay KS, et al. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. Thorax 1994;49(7):684-7
   PubMed Web of Science ®Google Scholar
• Halbert SA, Patton DL, Zarutskie PW, Soules MR. Function and structure of cilia in the fallopian tube of an infertile woman with Kartagener’s syndrome. Hum Reprod 1997;12(1):55-8
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Weitzberg E, Nordvall SL, et al. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener’s syndrome. Eur Respir J 1994;7(8):1501-4
   PubMed Web of Science ®Google Scholar
• Leigh MW, O’Callaghan C, Knowles MR. The challenges of diagnosing primary ciliary dyskinesia. Proc Am Thorac Soc 2011;8(5):434-7
   PubMedGoogle Scholar
• Knowles MR, Ostrowski LE, Leigh MW, et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med 2014;189(6):707-17
   PubMed Web of Science ®Google Scholar
• Knowles MR, Leigh MW, Carson JL, et al. Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. Thorax 2012;67(5):433-41
   PubMed Web of Science ®Google Scholar
• Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine. Johns Hopkins University, Baltimore, MD. Available from: http://omim.org [Cited 16 September 2014]
   Google Scholar
• Shapiro AJ, Weck KE, Chao KC, et al. Cri du chat syndrome and primary ciliary dyskinesia: a common genetic cause on chromosome 5p. J Pediatr 2014;165(4):858-61
   Google Scholar
• Randell SH, Boucher RC; University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006;35(1):20-8
   PubMed Web of Science ®Google Scholar
• Wanner A, Salathe M, O’Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996;154(6 Pt 1):1868-902
   PubMed Web of Science ®Google Scholar
• Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109(5):571-7
   PubMed Web of Science ®Google Scholar
• Marks JH. Airway clearance devices in cystic fibrosis. Paediatr Respir Rev 2007;8(1):17-23
   Google Scholar
• Elkins MR, Jones A, van der Schans C. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2006(2):CD003147
   Google Scholar
• Rogers D, Doull IJM. Physiological principles of airway clearance techniques used in the physiotherapy management of cystic fibrosis. Curr Paediatr 2005;15(3):233-8
   Google Scholar
• Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev 2002(3):CD002166
   Google Scholar
• Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis – a randomised controlled trial. Respir Res 2014;15:44
   PubMed Web of Science ®Google Scholar
• Webber BA, Hofmeyr JL, Morgan MD, Hodson ME. Effects of postural drainage, incorporating the forced expiration technique, on pulmonary function in cystic fibrosis. Br J Dis Chest 1986;80(4):353-9
   Google Scholar
• Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2014;7:CD006842
   Google Scholar
• Lee AL, Burge A, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2013;5:CD008351
   Google Scholar
• Phillips GE, Thomas S, Heather S, Bush A. Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge. Eur Respir J 1998;11(6):1389-91
   PubMed Web of Science ®Google Scholar
• Noone PG, Bennett WD, Regnis JA, et al. Effect of aerosolized uridine-5’-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. Am J Respir Crit Care Med 1999;160(1):144-9
   PubMed Web of Science ®Google Scholar
• Sutton PP, Gemmell HG, Innes N, et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988;43(1):57-60
   Google Scholar
• Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
   PubMed Web of Science ®Google Scholar
• Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
   PubMed Web of Science ®Google Scholar
• Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
   PubMed Web of Science ®Google Scholar
• Reeves EP, Williamson M, O’Neill SJ, et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183(11):1517-23
   PubMed Web of Science ®Google Scholar
• Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014;5:CD002996
   Google Scholar
• Bush A, Payne D, Pike S, et al. Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis. Chest 2006;129(1):118-23
   PubMed Web of Science ®Google Scholar
• Kupfer O, Wagner B, Knowles MR, et al. Airway inflammation in a large cohort of children with primary ciliary dyskinesia. American Thoracic Society International Conference, Philadelphia, PA. Am Thorac Soc 2013;A2086-A86
   Google Scholar
• Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012;11(2):78-83
   PubMed Web of Science ®Google Scholar
• Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24:739-45
   PubMed Web of Science ®Google Scholar
• Potter JL, Spector S, Matthews LW, Lemm J. Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1969;99(6):909-16
   Google Scholar
• Picot R, Das I, Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978;33(2):235-42
   PubMed Web of Science ®Google Scholar
• ten Berge M, Brinkhorst G, Kroon AA, de Jongste JC. DNase treatment in primary ciliary dyskinesia–assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999;27(1):59-61
   PubMed Web of Science ®Google Scholar
• Desai M, Weller PH, Spencer DA. Clinical benefit from nebulized human recombinant DNase in Kartagener’s syndrome. Pediatr Pulmonol 1995;20(5):307-8
   PubMed Web of Science ®Google Scholar
• El-Abiad NM, Clifton S, Nasr SZ. Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia. Respir Med 2007;101(10):2224-6
   PubMed Web of Science ®Google Scholar
• O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-34
   PubMed Web of Science ®Google Scholar
• Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013;7(1):65-75
   Web of Science ®Google Scholar
• Yaghi A, Zaman A, Dolovich MB. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J Aerosol Med Pulm Drug Deliv 2012;25(2):88-95
   PubMed Web of Science ®Google Scholar
• Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014;69(12):1073-9
   PubMed Web of Science ®Google Scholar
• Boogaard R, de Jongste JC, Merkus PJ. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol 2007;42(11):989-1001
   Google Scholar
• Stafanger G, Garne S, Howitz P, et al. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988;1(2):161-7
   PubMed Web of Science ®Google Scholar
• Loukides S, Kharitonov S, Wodehouse T, et al. Effect of arginine on mucociliary function in primary ciliary dyskinesia. Lancet 1998;352(9125):371-2
   Google Scholar
• Grasemann H, Gartig SS, Wiesemann HG, et al. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 1999;13(1):114-18
   Google Scholar
• Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non CFGG. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-58
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367-416
   PubMed Web of Science ®Google Scholar
• Sidhu MK, Mandal P, Hill AT. Bronchiectasis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2014;15(4):505-25
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014;44(2):382-93
   PubMed Web of Science ®Google Scholar
• Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93(7):476-80
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189(8):975-82
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-17
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1107-15
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251-9
   PubMed Web of Science ®Google Scholar
• Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014;6:CD010327
   Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
   PubMed Web of Science ®Google Scholar
• Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest 1996;109(6):1541-4
   PubMed Web of Science ®Google Scholar
• Macchiarini P, Chapelier A, Vouhe P, et al. Double lung transplantation in situs inversus with Kartagener’s syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg 1994;108(1):86-91
   Google Scholar
• Parsons DS, Greene BA. A treatment for primary ciliary dyskinesia: efficacy of functional endoscopic sinus surgery. Laryngoscope 1993;103(11 Pt 1):1269-72
   PubMed Web of Science ®Google Scholar
• Campbell R. Managing upper respiratory tract complications of primary ciliary dyskinesia in children. Curr Opin Allergy Clin Immunol 2012;12(1):32-8
   PubMed Web of Science ®Google Scholar
• Pruliere-Escabasse V, Coste A, Chauvin P, et al. Otologic features in children with primary ciliary dyskinesia. Arch Otolaryngol Head Neck Surg 2010;136(11):1121-6
   PubMedGoogle Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189(5):576-85
   PubMed Web of Science ®Google Scholar
• Foundation PCD. PCD Clinical and Research Centers: Overview & Updates. Primary Ciliary Dyskinesia Foundation. 2011. Available from: http://www.pcdfoundation.org/en/finding-a-cure/pcd-clinical-center [Cited 22 September 2014]
   Google Scholar
• BESTCILIA. BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia. 2014. Available from: http://www.bestcilia.eu/ [Cited 22 September 2014]
   Google Scholar
• Behan L, DunnGalvin A, Quittner AL, et al. Development of the QOL-PCD: a cross-cultural patient-reported outcome measure for adults with primary ciliary dyskinesia. European Respiratory Society International Congress Munich; Munich, Germany; 2014
   Google Scholar
• Dell S, Leigh M, Ferkol T, et al. Development of pediatric cross-cultural patient-reported outcome measures: QOL-PCD. European Respiratory Society International Congress Munich; Munich, Germany; 2014
   Google Scholar
• Lucas JS, Carroll M. Primary ciliary dyskinesia and cystic fibrosis: different diseases require different treatment. Chest 2014;145(4):674-6
   Google Scholar